GREAT POINT PARTNERS LLC
Q1 2024 Form 13-F

GREENWICH, CONNECTICUT
CIK 0001281446 · CRD 158423 · SEC-registered investment adviser
Consolidated report · includes 2 managers since Q3 2013
$641.6M Reported Value Total

GREAT POINT PARTNERS, LLC reports 20 total accounts under management (AUM). There are 20 discretionary accounts valued at $1,988,112,264, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
38 funds · $2.0B gross asset value
Private Equity Fund: $1.4B · Hedge Fund: $564.4M
Source: Form ADV filed 2026-03-31
Reported value
$641.6M
Quarter over quarter
+28.4%
Holdings
35
Top-10 concentration
51.6%

Filing Structure

Reports holdings for

  • JAY JEFFREY R · File #028-12517 · since Q3 2013
  • Nordahl Lillian (not a 13F filer in our records) · File #028-24470 · since Q3 2024
  • Yehudai Ortav · File #028-20398 · Q3 2020 – Q2 2024
  • KROIN DAVID (not a 13F filer in our records) · File #028-13262 · Q3 2013 – Q2 2020

Holdings reported by

Key People

Form ADV owners & control persons
Jeffrey Robert Jay
ELECTED MANAGER, MEMBER AND MANAGING DIRECTOR
Adam Brian Felsenthal
GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER
Ronald Marc Panzier
CHIEF OPERATING OFFICER AND CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2024 13F record

Q1 2024 13F filing summary

Q1 2024 Form 13F portfolio summary
Period of report March 31, 2024
Filed May 15, 2024
Form 13F-HR
Reported value $641.6M
Positions 35
Change in reported value +9.4%
New positions 10
Exited positions 9
Position turnover 43.2%
Top-10 concentration 51.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
41 $418.5M
Q2 2026 13F
Filed Aug 14, 2026
37 $529.1M
Q1 2026 13F
Filed May 15, 2026
39 $435.1M
Q4 2025 13F
Filed Feb 17, 2026
29 $308.4M
Q3 2025 13F
Filed Nov 14, 2025
28 $242.5M
Q2 2025 13F
Filed Aug 14, 2025
26 $153.8M
Q1 2025 13F
Filed May 15, 2025
31 $188.8M
Q4 2024 13F
Filed Feb 14, 2025
26 $212.2M
Q3 2024 13F
Filed Nov 13, 2024
29 $339.8M
Q2 2024 13F
Filed Aug 14, 2024
33 $522.0M
Q1 2024 13F
Filed May 15, 2024
35 $641.6M
Q4 2023 13F
Filed Feb 14, 2024
34 $586.7M
Q3 2023 13F
Filed Nov 14, 2023
39 $549.0M
Q2 2023 13F
Filed Aug 14, 2023
36 $510.8M
Q1 2023 13F
Filed May 15, 2023
42 $509.3M
Q4 2022 13F
Filed Feb 14, 2023
40 $510.2M
Q3 2022 13F
Filed Nov 14, 2022
40 $415.3M
Q2 2022 13F
Filed Aug 15, 2022
33 $417.0M
Q1 2022 13F
Filed May 16, 2022
29 $413.8M
Q4 2021 13F
Filed Feb 14, 2022
35 $450.1M

33 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2024

Largest Q1 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 NGNE NEUROGENE INC $51.1M 7.97%
2 ALPN ALPINE IMMUNE SCIENCES INC $44.7M 6.97%
3 URGN UROGEN PHARMA LTD $39.3M 6.13%
4 ABVX ABIVAX SA $35.6M 5.55%
5 EOLS EVOLUS INC $34.3M 5.35%
6 PLRX PLIANT THERAPEUTICS INC $27.6M 4.3%
7 APGE APOGEE THERAPEUTICS INC $26.6M 4.14%
8 AVTE AEROVATE THERAPEUTICS INC $26.2M 4.09%
9 VRDN VIRIDIAN THERAPEUTICS INC $23.4M 3.64%
10 ANAB ANAPTYSBIO INC $22.0M 3.43%
11 ESPR ESPERION THERAPEUTICS INC NE $21.4M 3.34%
12 INSM INSMED INC $21.0M 3.28%
13 ACLX ARCELLX INC $20.9M 3.25%
14 XENE XENON PHARMACEUTICALS INC $19.6M 3.06%
15 MNMD MIND MEDICINE MINDMED INC $18.8M 2.93%
16 DNTH DIANTHUS THERAPEUTICS INC $18.8M 2.92%
17 OTLK OUTLOOK THERAPEUTICS INC $17.7M 2.75%
18 FOLD AMICUS THERAPEUTICS INC $17.6M 2.75%
19 OCUL OCULAR THERAPEUTIX INC $15.7M 2.45%
20 DVAX DYNAVAX TECHNOLOGIES CORP $15.7M 2.45%

Values as reported on the Q1 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings